GuangzhouApril 29, 2026 /PRNewswire/ — Recently, the FFC 2026 Functional Food Conference was held in Hangzhou, Zhejiang Province. Ma Jun, Vice President and Chief Science and Technology Officer of Infinitus (China) Company Ltd., was invited to attend the conference and delivered a keynote speech, introducing the company’s scientific research accumulation and innovative practices in the field of functional foods. He specifically highlighted the results of a randomized, double-blind, placebo-controlled human clinical trial on the core product, Zengjian Oral Liquid, in enhancing immunity.
This conference, themed “Functional Foods and Human Health,” was co-organized by the FFC Functional Food Conference Organizing Committee and the National Functional Food Engineering Technology Research Center of Jiangnan University, among others. It brought together over 3,000 industry experts, corporate representatives, and researchers from both domestic and international backgrounds, focusing on core topics such as technological innovation in functional foods, product development, and industry growth. As a highly influential professional exchange platform in China’s functional food sector, it plays a significant role in guiding the industry’s high-quality development.
FFC 2026 Functional Food Conference Scene
In his speech, Mr. Ma Jun systematically elaborated on Infinitus’s user-needs-driven research system, introducing the company’s scientific philosophy and practical approaches to product efficacy validation. He stated that Infinitus consistently adheres to a user-centric approach in efficacy validation, leveraging Chinese herbal medicine technology to build a complete scientific framework of “material basis—precise evaluation—gold standard validation.” Building on accumulated research at the cellular, model organism, and animal experiment levels, the company continues to advance human evidence-based studies, supporting product efficacy with scientific data and contributing to the standardized development of the industry.
Mr. Ma Jun Delivering a Thematic Presentation
The clinical trial results of Zengjian Oral Liquid shared at this conference represent a significant breakthrough in Infinitus’s evidence-based research. The study adopted a multi-center, randomized, double-blind, parallel-controlled design, recognized as the highest standard “gold standard” in evidence-based medicine, aimed at precisely validating the product’s improvement of human immune function in real-world scenarios.
Research data shows[1] that after 45 days of taking Zengjian Oral Liquid, the subjects’ Systemic Immune Vigor (SIV) index significantly improved from level 3 to level 4, with more pronounced effects observed in women and individuals aged 55 and above. After 90 days of consumption, the number of immune reserve cells (naïve CD8+ T cells) in the subjects significantly increased, and levels of immunoglobulins IgG and IgM also showed notable elevation. This fully demonstrates that the product can effectively enhance the body’s immune reserve capacity and defense capabilities, providing scientific support for immune regulation.
As a company deeply rooted in the field of Chinese herbal medicine health products, Infinitus is committed to promoting the excellent traditional Chinese health culture. By leveraging modern science and technology to explore the health value of traditional Chinese herbs, the company has built a full-chain innovation system of “research—technology—product.” At this conference, Infinitus injected new momentum into the high-quality development of the functional food industry with its solid scientific achievements and clear practical pathways.
Looking ahead, Infinitus will continue to vigorously advance Chinese herbal medicine technology, focusing on consumer health needs to develop more high-quality, trustworthy Chinese herbal health products. Through scientific evidence-based approaches, it aims to support the standardized development of the industry, providing the public with more targeted health solutions and safeguarding national health.